Skandinaviska Enskilda Banken AB publ Sells 29,069 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Skandinaviska Enskilda Banken AB reduced its stake in Krystal Biotech by 32.6%, holding 59,978 shares worth approximately $10.8 million after selling 29,069 shares in Q1.
• Several hedge funds have increased their positions in Krystal Biotech, with Fifth Third Bancorp growing its stake by 159.1% during the same period.
• Analysts remain optimistic, with a consensus rating of "Buy" for Krystal Biotech, and target prices ranging from $176 to $240 per share.

Skandinaviska Enskilda Banken AB publ lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 32.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,978 shares of the company's stock after selling 29,069 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.21% of Krystal Biotech worth $10,814,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in KRYS. Crossmark Global Holdings Inc. boosted its stake in shares of Krystal Biotech by 2.7% during the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after buying an additional 63 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Krystal Biotech by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after buying an additional 82 shares during the last quarter. Xponance Inc. lifted its position in Krystal Biotech by 4.9% during the first quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after acquiring an additional 88 shares during the last quarter. New York State Teachers Retirement System lifted its position in Krystal Biotech by 0.6% during the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after acquiring an additional 100 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

Shares of KRYS stock traded up $2.61 during mid-day trading on Wednesday, hitting $154.69. The company's stock had a trading volume of 71,020 shares, compared to its average volume of 315,719. The company's fifty day simple moving average is $139.09 and its 200-day simple moving average is $155.65. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $212.06. The company has a market cap of $4.47 billion, a PE ratio of 37.23 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KRYS shares. Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Friday, July 25th. Citigroup restated a "neutral" rating and set a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Guggenheim decreased their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Friday, July 25th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $211.33.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).